CNKI中单抗药物治疗系统性红斑狼疮的文献计量分析

Bibliometric Analysis of Monoclonal Antibody Therapy for Systemic Lupus Erythematosus in CNKI

摘要: 目的：系统性红斑狼疮(SLE)是一种多系统受累的自身免疫病，单抗类药物的应用显著改善了疾病管理。本研究旨在通过文献计量学分析，探讨国内单抗类药物治疗SLE的研究现状、热点及发展趋势。方法：检索中国学术期刊全文数据库(CNKI) 2000年1月1日至2024年8月25日的相关文献，提取期刊、作者、机构、关键词、基金等数据，采用Excel 2019进行统计分析。结果：共纳入298篇文献，年发文量呈上升趋势，2022~2023年达峰值(各36篇)。载文期刊以《中华临床免疫和变态反应杂志》(10篇)、《中国实用儿科杂志》(8篇)为主。上海交通大学(26篇)、中南大学(23篇)为高产机构。关键词分析显示研究热点集中于贝利尤单抗、利妥昔单抗及狼疮性肾炎治疗。35.57%文献获基金支持，其中国家自然科学基金占比最高(29项次)。

Abstract: Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with multi-organ involvement. Monoclonal antibodies (mAbs) have shown promise in improving disease activity and reducing glucocorticoid dependence. This study aimed to analyze the research trends, hotspots, and collaborative networks of mAb therapy for SLE in China using bibliometric methods. Methods: We systematically retrieved literature from the China National Knowledge Infrastructure (CNKI) database (January 2000~August 2024) using keywords related to SLE and mAbs. Data on publication year, journal, authors, institutions, keywords, and funding sources were extracted and analyzed. Results: A total of 298 articles were included. Annual publications showed an increasing trend, peaking in 2022~2023 (36 articles/year). Core journals included Chinese Journal of Allergy & Clinical Immunology (10 articles) and Chinese Journal of Practical Pediatrics (8 articles). Leading institutions were Shanghai Jiao Tong University (26 articles) and Central South University (23 articles). Keyword analysis revealed research hotspots such as belimumab, rituximab, and lupus nephritis. Only 35.57% of studies received funding, primarily from the National Natural Science Foundation of China (29 grants).